로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Siglec-3

Siglec-3

요약

Name:Myeloid cell surface antigen CD33
Target Synonym:Myeloid Cell Surface Antigen CD33,CD33 Molecule Transcript,CD33 Antigen,Siglec-3,P67,FLJ00391,Sialic acid-binding Ig-like lectin 3,CD33,CD33 Molecule,CD33 Antigen (Gp67),SIGLEC3,Gp67,Sialic Acid Binding Ig-Like Lectin 3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

CD3-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Siglec-3, His Tag (Cat. No. CD3-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CD3-HF224-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human Siglec-3, His Tag (Cat. No.CD3-HF224) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

CD3-H5259-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Siglec-3 MAb (Mouse IgG1) on AMC Biosensor, can bind Human Siglec-3, Llama IgG2b Fc Tag, low endotoxin (Cat. No. CD3-H5259) with an affinity constant of 0.365 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD3-H5257-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Siglec-3 MAb (Mouse IgG1) on AMC Biosensor, can bind Human Siglec-3, Fc Tag (Cat. No. CD3-H5257) with an affinity constant of 0.329 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CD33,SIGLEC3,gp67

Background

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Gemtuzumab ozogamicin WAY-CMA-676; CL-555201; CMA-676; CDP-771; hP67.6-calicheamicin Approved Pfizer Inc, Ucb Sa Mylotarg EU Leukemia, Myeloid, Acute Pfizer Europe Ma Eeig 2008-01-18 Leukemia, Myeloid; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Lintuzumab-gelonin conjugate Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
CART-33 (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia, Myeloid, Acute Details
Anti-CD33/CLL-1 CAR-T (Legend) Phase 1 Clinical Leukemia, Promyelocytic, Acute Details
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) Clinical Wuhan Bio-Raid Biotechnology Leukemia, Myeloid, Acute Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) Phase 1 Clinical University Of California San Diego Leukemia, Myeloid, Acute Details
Lintuzumab Ac-225/Venetoclax Phase 1 Clinical Actinium Pharmaceuticals Leukemia, Promyelocytic, Acute Details
ICG-136 ICG-136; 123b-33bcCAR Phase 1 Clinical Leukemia, Myeloid, Acute Details
Vadastuximab talirine 33-A; SGN-CD33A Seattle Genetics Details
Anti-CD33 CAR-NK cell therapy (Sichuan Kelun-Biotech) Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Details
CD33xCD3 Bispecific Antibody (Y-mAbs Therapeutics) Y-Mabs Therapeutics Inc Details
Anti-CD33/CLL1 CAR-NK Cell Therapy Phase 1 Clinical Amador Biomedicine (Hangzhou) Co Ltd Leukemia, Myeloid, Acute Details
Eluvixtamab MT-114; AMG-330 Phase 1 Clinical Amgen Inc Myelodysplastic Syndromes Details
IMGN-779 IMGN-779 Immunogen Inc Details
JNJ-67571244 JNJ-67571244; JNJ-67371244; JNJ-1244 Johnson & Johnson Details
OXS-3550 OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE Oxis Biotech, University Of Minnesota Details
IM73 chimeric antigen receptor T cell therapy IM-73-CAR-T Beijing Immunochina Medical Science & Technology Co Ltd Leukemia, Myeloid, Acute Details
Lintuzumab Bi-213 Pdl Biopharma Details
Anti-CD33 CAR-NK cell therapy (PersonGen Biomedicine) Details
Anti-CD33 chimeric antigen receptor T cell therapy (Intrexon/ZIOPHARM Oncology) Ziopharm Oncology, Intrexon Co Details
GEM-333 GEM-333 Gemoab Monoconals Details
Lintuzumab Ac-225 (Actinium Pharmaceuticals) 225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 Pdl Biopharma Details
BI-836858 BI-836858 C.H. Boehringer Sohn Ag & Co. Kg Details
PRGN-3006 PRGN-3006 Precigen Details
Emerfetamab AMG-673; AMG673 Phase 1 Clinical Amgen Inc Leukemia, Myeloid, Acute Details
CD33 CAR T Cells(Beijing Boren Hospital) Phase 1 Clinical Beijing Gao Boren Hospital Co Ltd Neoplasms Details
CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) CLL1-CD33-cCAR Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd, Chengdu Military General Hospital Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
CD123-CD33 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute Details
Lintuzumab SGN-33; HuM-195 Phase 2 Clinical Pdl Biopharma Leukemia; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Breast Neoplasms; Leukemia, Myeloid, Acute Details
anti-CD33 CAR T cells therapy(iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Hematologic Neoplasms; Leukemia, Myeloid, Acute Details
AL-003 AL-003 Phase 1 Clinical Abbvie Inc, Alector Alzheimer Disease Details
Vixtimotamab T-564; AMV-564 Phase 1 Clinical Amphivena Therapeutics Solid tumours; Myelodysplastic Syndromes Details
CLL1+CD33 CAR-T(Zhejiang University) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details
CD33 CAR-T Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop